CN102753199A - 癌干细胞标记物及其用途 - Google Patents

癌干细胞标记物及其用途 Download PDF

Info

Publication number
CN102753199A
CN102753199A CN2011800065922A CN201180006592A CN102753199A CN 102753199 A CN102753199 A CN 102753199A CN 2011800065922 A CN2011800065922 A CN 2011800065922A CN 201180006592 A CN201180006592 A CN 201180006592A CN 102753199 A CN102753199 A CN 102753199A
Authority
CN
China
Prior art keywords
cancer
cells
tumor
cancer stem
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800065922A
Other languages
English (en)
Chinese (zh)
Inventor
S·戈勒茨
U·卡斯滕
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glycotope GmbH
Original Assignee
Glycotope GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycotope GmbH filed Critical Glycotope GmbH
Publication of CN102753199A publication Critical patent/CN102753199A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5756—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving tumour-associated glycolinkage [TAG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN2011800065922A 2010-01-20 2011-01-20 癌干细胞标记物及其用途 Pending CN102753199A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US29673810P 2010-01-20 2010-01-20
US61/296,738 2010-01-20
EP10000527.1 2010-01-20
EP10000527A EP2347769A1 (en) 2010-01-20 2010-01-20 Cancer stem cell markers and uses thereof
PCT/EP2011/000217 WO2011089004A1 (en) 2010-01-20 2011-01-20 Cancer stem cell markers and uses thereof

Publications (1)

Publication Number Publication Date
CN102753199A true CN102753199A (zh) 2012-10-24

Family

ID=42173400

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011800065922A Pending CN102753199A (zh) 2010-01-20 2011-01-20 癌干细胞标记物及其用途

Country Status (8)

Country Link
US (1) US20120294859A1 (enExample)
EP (2) EP2347769A1 (enExample)
JP (2) JP2013517487A (enExample)
CN (1) CN102753199A (enExample)
AU (1) AU2011208874B2 (enExample)
BR (1) BR112012018132A2 (enExample)
CA (1) CA2786212A1 (enExample)
WO (1) WO2011089004A1 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103969437A (zh) * 2014-04-22 2014-08-06 广州恒泰生物科技有限公司 用于卵巢癌早中期快速诊断试剂盒的制备方法
CN111363008A (zh) * 2020-03-18 2020-07-03 北京鼎成肽源生物技术有限公司 一种输卵管癌靶标抗原组合、输卵管癌靶标抗原组合刺激培养的ctl细胞及其应用
CN113804531A (zh) * 2021-09-10 2021-12-17 北京大学 一种细胞高活性染色方法
CN115916349A (zh) * 2020-06-30 2023-04-04 葛莱高托普有限公司 针对Lewis Y的人源化抗体
CN116718774A (zh) * 2023-07-07 2023-09-08 杭州准星医学科技有限公司 一种用于肿瘤体外诊断的试剂盒及其使用方法

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
JP5986745B2 (ja) 2008-07-15 2016-09-06 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ Ｐｔｆｅ様のアルミニウム・コート・ガラススライド上のグリカンアレイおよび関連する方法
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
WO2011130332A1 (en) 2010-04-12 2011-10-20 Academia Sinica Glycan arrays for high throughput screening of viruses
US9778264B2 (en) 2010-09-03 2017-10-03 Abbvie Stemcentrx Llc Identification and enrichment of cell subpopulations
SG189212A1 (en) 2010-09-03 2013-05-31 Stem Centrx Inc Identification and enrichment of cell subpopulations
WO2012039430A1 (ja) * 2010-09-21 2012-03-29 株式会社Ｇｐバイオサイエンス がん幹細胞の単離方法
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
WO2014031498A1 (en) 2012-08-18 2014-02-27 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
US20160025717A1 (en) 2013-03-14 2016-01-28 Emory University Hyposialylation disorders
US10086054B2 (en) 2013-06-26 2018-10-02 Academia Sinica RM2 antigens and use thereof
WO2014210564A1 (en) 2013-06-27 2014-12-31 Academia Sinica Glycan conjugates and use thereof
JP6486368B2 (ja) 2013-09-06 2019-03-20 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 改変されたグリコシル基を含む糖脂質を用いたヒトｉＮＫＴ細胞の活性化
RU2666141C2 (ru) 2013-09-17 2018-09-06 Оби Фарма, Инк. Композиции углеводной вакцины для индукции иммунного ответа и их применение при лечении рака
TW201620939A (zh) 2014-01-16 2016-06-16 中央研究院 治療及檢測癌症之組合物及方法
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
EP3129767B1 (en) 2014-03-27 2021-09-01 Academia Sinica Reactive labelling compounds and uses thereof
US10023651B2 (en) 2014-04-18 2018-07-17 The Research Foundation For The State University Of New York Humanized anti-TF-antigen antibodies
AU2015247358B2 (en) * 2014-04-18 2020-02-27 The Research Foundation For The State University Of New York Humanized anti-TF-antigen antibodies
AU2015267045B2 (en) 2014-05-27 2021-02-25 Academia Sinica Anti-HER2 glycoantibodies and uses thereof
DK3149045T3 (da) 2014-05-27 2023-03-06 Academia Sinica Sammensætninger og fremgangsmåder vedrørende universelle glycoformer til forbedret antistofeffekt
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
KR20170003720A (ko) 2014-05-27 2017-01-09 아카데미아 시니카 항-ｃｄ20 글리코항체 및 이의 용도
JP7063538B2 (ja) 2014-05-28 2022-05-09 アカデミア シニカ 抗ＴＮＦα糖操作抗体群およびその使用
EP3191500A4 (en) 2014-09-08 2018-04-11 Academia Sinica HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS
US20170306046A1 (en) 2014-11-12 2017-10-26 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
US10342858B2 (en) 2015-01-24 2019-07-09 Academia Sinica Glycan conjugates and methods of use thereof
KR102630294B1 (ko) * 2015-01-24 2024-01-26 아카데미아 시니카 암 마커 및 이를 사용하는 방법
US10493087B2 (en) 2015-02-25 2019-12-03 The United States of America, as represented by National Institute of Health Sialylation-increasing therapies for diseases associated with oxidative stress
JP2018532990A (ja) 2015-09-04 2018-11-08 オービーアイ ファーマ，インコーポレイテッド グリカンアレイおよび使用の方法
CN108463248B (zh) 2015-11-12 2022-10-21 西雅图基因公司 聚糖相互作用化合物及使用方法
WO2017100796A1 (en) * 2015-12-11 2017-06-15 SINACA, Academia Modulation of globoseries glycosphingolipid synthesis and cancer biomarkers
AU2017231749A1 (en) 2016-03-08 2018-09-20 Academia Sinica Methods for modular synthesis of N-glycans and arrays thereof
US10980894B2 (en) 2016-03-29 2021-04-20 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
US11041017B2 (en) 2016-03-29 2021-06-22 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
KR20250048399A (ko) 2016-04-22 2025-04-08 오비아이 파머 인코퍼레이티드 글로보 계열 항원을 통한 면역 활성화 또는 면역 조정에 의한 암 면역요법
WO2018022933A1 (en) 2016-07-27 2018-02-01 Obi Pharma, Inc. Immunogenic/therapeutic glycan compositions and uses thereof
EP3491026A4 (en) 2016-07-29 2020-07-29 OBI Pharma, Inc. HUMAN ANTIBODIES, PHARMACEUTICAL COMPOSITIONS AND PROCESSES
AU2017316663B2 (en) 2016-08-22 2024-02-22 CHO Pharma Inc. Antibodies, binding fragments, and methods of use
EP3541847A4 (en) 2016-11-17 2020-07-08 Seattle Genetics, Inc. COMPOUNDS INTERACTING WITH GLYCANE AND METHODS OF USE
MY195529A (en) 2016-11-18 2023-01-30 Astellas Pharma Inc Novel Anti-Human MUC1 Antibody Fab Fragment
JP2019535731A (ja) 2016-11-21 2019-12-12 オービーアイ ファーマ，インコーポレイテッド コンジュゲートさせた生物学的分子、医薬組成物及び方法
EP3589319A4 (en) 2017-03-03 2021-07-14 Seagen Inc. GLYCAN INTERACTING COMPOUNDS AND METHOD OF USE
CA3055438A1 (en) * 2017-03-29 2018-10-04 Glycotope Gmbh Multispecific antibody constructs binding to muc1 and cd3
TWI795415B (zh) 2017-07-07 2023-03-11 日商安斯泰來製藥股份有限公司 新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段
BR122023024273A2 (pt) 2018-02-27 2024-02-20 Incyte Corporation Compostos imidazopirimidinas e triazolopirimidinas, seus usos, método para inibir uma atividade de um receptor de adenosina e composição farmacêutica dos mesmos
PT110722B (pt) * 2018-05-03 2021-08-17 Instituto De Patologia E Imunologia Molecular Da Univ Do Porto Ipatimup Uso de anticorpos para o antigénio thomsen-friedenreich num método e estojo para avaliação de instabilidade de microsatelites
WO2019221269A1 (ja) 2018-05-17 2019-11-21 アステラス製薬株式会社 抗ヒトＭＵＣ１抗体Ｆａｂフラグメント、ペプチドリンカー及び／又は配位子を含む複合体
HRP20240756T1 (hr) 2018-05-18 2024-09-13 Daiichi Sankyo Co., Ltd. Anti-muc1-eksatekan antitijelo-lijek konjugat
EP3810610A1 (en) 2018-05-18 2021-04-28 Incyte Corporation Fused pyrimidine derivatives as a2a / a2b inhibitors
US11203645B2 (en) 2018-06-27 2021-12-21 Obi Pharma, Inc. Glycosynthase variants for glycoprotein engineering and methods of use
AU2019297361B2 (en) 2018-07-05 2024-06-27 Incyte Corporation Fused pyrazine derivatives as A2A / A2B inhibitors
MY205764A (en) 2018-10-10 2024-11-12 Astellas Pharma Inc Pharmaceutical composition containing tagged site-antihuman antibody fab fragment complex
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
CN110161241A (zh) * 2019-04-30 2019-08-23 丁晓昆 一种快速检测生物组织切片cosmc基因突变试剂盒
KR20220137013A (ko) 2020-01-03 2022-10-11 인사이트 코포레이션 Cd73 억제제 및 a2a/a2b 아데노신 수용체 억제제 병용 요법
CR20220317A (es) 2020-01-03 2022-09-02 Incyte Corp Anticuerpos anti-cd73 y usos de estos
TW202241441A (zh) 2020-12-29 2022-11-01 美商英塞特公司 包含ａ２ａ／ａ２ｂ抑制劑、ｐｄ－１／ｐｄ－ｌ１抑制劑及抗ｃｄ７３抗體之組合療法
WO2022157422A1 (en) * 2021-01-25 2022-07-28 Kaivogen Oy Use of a fuc-alpha(1-2)-gal glycan structure as a biomarker for bladder cancer
WO2023023840A1 (en) * 2021-07-16 2023-03-02 Université de Montréal Novel tumor-specific antigens for cancer stem cells and uses thereof
CN115960169A (zh) * 2021-10-09 2023-04-14 清华大学深圳国际研究生院 特异性靶向非小细胞肺癌肿瘤干细胞的多肽及其应用
CN119955728A (zh) * 2022-08-01 2025-05-09 首都医科大学附属北京胸科医院 恶性表型大细胞肺癌细胞株及其应用
CN121319187B (zh) * 2025-12-08 2026-03-17 宁波大学附属第一医院 一种与cd176蛋白结合的羊驼源纳米抗体及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020192223A1 (en) * 1989-06-30 2002-12-19 Ingegerg Hellstrom Novel antibody conjugates reactive with human carcinomas
US20060251668A1 (en) * 2002-11-29 2006-11-09 Steffen Goletz Tumor-specific recognition molecules
US7374755B2 (en) * 2004-07-26 2008-05-20 The Research Foundation Of State University Of New York Therapeutic use of anti-TF-Antigen antibody
US20090041836A1 (en) * 2006-01-03 2009-02-12 University Of Georgia Research Foundation, Inc. Glycolipopeptide and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1654353B1 (en) 2003-08-18 2013-05-22 Glycotope GmbH Tumour cell lines nm-f9 (dsm acc2606) and nm-d4 (dsm acc2605), uses threreof
WO2007140011A2 (en) * 2006-05-26 2007-12-06 The Government Of The United States Of America Erythroid progenitor cells and methods for producing parvovirus b19 therein

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020192223A1 (en) * 1989-06-30 2002-12-19 Ingegerg Hellstrom Novel antibody conjugates reactive with human carcinomas
US20060251668A1 (en) * 2002-11-29 2006-11-09 Steffen Goletz Tumor-specific recognition molecules
US7374755B2 (en) * 2004-07-26 2008-05-20 The Research Foundation Of State University Of New York Therapeutic use of anti-TF-Antigen antibody
US20090041836A1 (en) * 2006-01-03 2009-02-12 University Of Georgia Research Foundation, Inc. Glycolipopeptide and uses thereof

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103969437A (zh) * 2014-04-22 2014-08-06 广州恒泰生物科技有限公司 用于卵巢癌早中期快速诊断试剂盒的制备方法
CN111363008A (zh) * 2020-03-18 2020-07-03 北京鼎成肽源生物技术有限公司 一种输卵管癌靶标抗原组合、输卵管癌靶标抗原组合刺激培养的ctl细胞及其应用
CN113388023A (zh) * 2020-03-18 2021-09-14 北京鼎成肽源生物技术有限公司 一种输卵管癌靶标抗原、输卵管癌靶标抗原刺激培养的ctl细胞及其应用
CN113429473A (zh) * 2020-03-18 2021-09-24 北京鼎成肽源生物技术有限公司 一种输卵管癌靶标抗原、输卵管癌靶标抗原刺激培养的ctl细胞及其应用
CN111363008B (zh) * 2020-03-18 2021-11-16 北京鼎成肽源生物技术有限公司 一种输卵管癌靶标抗原组合、输卵管癌靶标抗原组合刺激培养的ctl细胞及其应用
CN113429473B (zh) * 2020-03-18 2022-11-04 北京鼎成肽源生物技术有限公司 一种输卵管癌靶标抗原、输卵管癌靶标抗原刺激培养的ctl细胞及其应用
CN115916349A (zh) * 2020-06-30 2023-04-04 葛莱高托普有限公司 针对Lewis Y的人源化抗体
US12415864B2 (en) 2020-06-30 2025-09-16 Pentixapharm Ag Humanized antibodies against Lewis Y
CN113804531A (zh) * 2021-09-10 2021-12-17 北京大学 一种细胞高活性染色方法
CN113804531B (zh) * 2021-09-10 2024-02-06 北京大学 一种细胞高活性染色方法
CN116718774A (zh) * 2023-07-07 2023-09-08 杭州准星医学科技有限公司 一种用于肿瘤体外诊断的试剂盒及其使用方法

Also Published As

Publication number Publication date
BR112012018132A2 (pt) 2017-06-20
EP2525832A1 (en) 2012-11-28
AU2011208874B2 (en) 2015-06-25
CA2786212A1 (en) 2011-07-28
AU2011208874A1 (en) 2012-08-02
EP2347769A1 (en) 2011-07-27
JP2016047848A (ja) 2016-04-07
JP2013517487A (ja) 2013-05-16
US20120294859A1 (en) 2012-11-22
WO2011089004A1 (en) 2011-07-28

Similar Documents

Publication Publication Date Title
AU2011208874B2 (en) Cancer stem cell markers and uses thereof
JP5689133B2 (ja) 結腸直腸癌におけるｐｏｄｘｌタンパク質
JP7022191B2 (ja) 前立腺がんの分析のための組成物及び方法
US20220365088A1 (en) Autoantibody biomarkers of ovarian cancer
JP6795813B2 (ja) がん細胞の検出方法、がん細胞内に物質を導入するための試薬、及びがん治療用組成物
JPWO2008056833A1 (ja) ｉｎｖｉｖｏで抗腫瘍活性を有する抗ヒトＤｌｋ−１抗体
JP2020125352A (ja) 抗−ｃｄ４３抗体およびその癌治療用途
RU2641968C2 (ru) Композиции и способы анализа рака предстательной железы
US12091457B2 (en) Use for preventing and treating myeloid-derived suppressor cell-related diseases
CN101553259A (zh) 显示cd63表面表达的细胞的细胞毒性介导
JP2019528437A (ja) 腫瘍関連マクロファージをターゲティングすることによるガン疾患の処置方法
Wagner et al. Two birds with one stone: human SIRPα nanobodies for functional modulation and in vivo imaging of myeloid cells
Lin et al. Co-expression of CD173 (H2) and CD174 (Lewis Y) with CD44 suggests that fucosylated histo-blood group antigens are markers of breast cancer-initiating cells
US9512223B2 (en) Methods for treatment of gastric cancer
JP2022520383A (ja) 癌細胞上に存在するケラチン１４（ｋｒｔ１４）の細胞外部分を標的とすることによる癌の治療または予防のための方法
JP5339676B2 (ja) 細胞を検出する方法、およびこれに有用な薬剤
JP2022530339A (ja) インテグリンα１０および侵攻性癌型
US9206258B2 (en) Anti-prostate cancer antibodies and methods of detection and treatment of prostate cancer using the same
WO2025026204A1 (en) Antibodies against ror1 and uses thereof
WO2020171171A1 (ja) 抗ｈｌａ－ｄｒ抗体、およびそのがん治療用途
US20130143231A1 (en) MST1/STK4 PHOSPHO-THREONINE 120 (pMST-T120) ANTIBODY
BR112018007334B1 (pt) Anticorpo anti-cd43, conjugado e composição do mesmo para tratamento de câncer
HK1255484B (en) Compositions and methods for prostate cancer analysis
HK1255484A1 (en) Compositions and methods for prostate cancer analysis

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20121024

RJ01 Rejection of invention patent application after publication